Intec Pharma Ltd (NTEC) Gets a Buy Rating from Oppenheimer


In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Intec Pharma Ltd (NTEC). The company’s shares opened today at $6.76.

According to TipRanks.com, Olson is a 1-star analyst with an average return of -2.3% and a 45.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.

Intec Pharma Ltd has an analyst consensus of Strong Buy, with a price target consensus of $15, representing a 121.9% upside. In a report issued on March 5, Ladenburg also maintained a Buy rating on the stock with a $15 price target.

See today’s analyst top recommended stocks >>

Based on Intec Pharma Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.6 million. In comparison, last year the company had a GAAP net loss of $10.24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts